RUXIENCE
(Ruxience)Phase 3Biologic
RUXIENCE is one of 59 biologic programs targeting Hairy Cell Leukemia. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
58
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
#DrugCompanyPhaseTrials
1Zydelig
GileadApproved
Rituxan
RochePhase 3
Jaypirca
Eli LillyPhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Nemtabrutinib
Merck & Co.Phase 3
Venclexta
AbbViePhase 2
Gazyva
RochePhase 2
Beqalzi
BBeOne Medicines
Phase 3
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial
Regulatory
FDA Approval Timeline[4]
Jul 23, 2019
RUXIENCE
BLA BLA761103
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ruxience. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details